The acquisition of new gain-of-function mutations in signaling genes (FLT3, WT1, PTPN11, NRAS), NPM1, or IDH1/2 in the setting of MDS heralds transformation to AML (49, 73). The gene discussed is NRAS; the disease is myelodysplastic syndrome.